Immunomedics (IMMU) Misses Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Immunomedics Reports Third Quarter 2019 Results and Provides Corporate Update
October 30, 2019 4:01 PM EDTTROPHY-U-01 Reached Target Enrollment in Cisplatin-Eligible Cohort of 100 Patients
First NSCLC Patient Dosed in Trop-2-Enriched TROPiCS-03 Study
BLA Resubmission Targeted for Late November/Early December 2019
MORRIS PLAINS, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (Immunomedics or the Company), a leading biopharmaceutical company in... More
